Aucatzyl
Prescribing Information
Adverse Event Reporting
Autolus Assist

Patient Eligibility

AUCATZYL is recommended by NICE for eligible patients in England, Wales and Northern Ireland1,2

Knowing which patients may be eligible for AUCATZYL is an important part of treatment planning

AUCATZYL is indicated for the treatment of adult patients years) with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia.3

Explore the practical eligibility considerations to help identify appropriate adults with R/R B-ALL.

Play video

Understanding eligibility

Watch Dr Michelle Lannon share practical insights on identifying and referring appropriate adults with R/R
B-ALL for AUCATZYL

NICE reimbursement

NICE recommends AUCATZYL to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in people aged ≥26 years in England, Wales and Northern Ireland1,2

Summary of CDF/NHSE eligibility criteria4

Eligibility criteria summary chart for patients aged 26 or older with B-ALL. Criteria include ECOG performance status 0-1, sufficient end organ function, CD19-positive B-ALL detected in the marrow, Ph-positive or Ph-negative disease, and no active CNS disease. The chart separates criteria by patients with no prior allo-SCT eligibility and those with prior allo-SCT eligibility, including refractory B-ALL, bone marrow relapse scenarios, relapse timing after allo-SCT, and absence of active GvHD.

For complete criteria please see the National Cancer Drugs Fund List.
For patient referrals, speak to your local ATC or contact the ALL panel by emailing the-christie.adultallpanel@nhs.net

Play video

Real-world experience with AUCATZYL

Watch experts share early real world insights into AUCATZYL, from CAR T-cell pathway implementation and MDT coordination to translating trial experience into clinical practice

Process and administration

Learn more about tumour-guided split dosing and how to administer AUCATZYL.

Treatment centres

Locate your nearest centre accepting patient referrals 
for AUCATZYL.

Stay updated

Sign up to receive the latest news and product updates from Autolus.

Receive key updates

By clicking ‘Receive key updates’ you’re confirming that you agree with our Terms and conditions.

Indication

Aucatzyl is indicated for the treatment of adult patients (≥18 years) with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia.3

NICE Reimbursement

NICE recommends AUCATZYL to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in people aged ≥26 years in England, Wales and Northern Ireland.1,2

ALL=acute lymphoblastic leukaemia, allo-SCT=allogeneic stem cell transplant, B-ALL=B-cell precursor acute lymphoblastic leukaemia, ATC=Authorised Treatment Centre, BM=bone marrow, CAR=chimeric antigen receptor, CDF=Cancer Drugs Fund, CNS=central nervous system, CR=complete remission, ECOG PS=Eastern Cooperative Oncology Group performance status, EMD=extramedullary disease, GvHD=graft vs host disease, IS=immunosuppression, MDT=multidisciplinary team, NHSE=NHS England, NICE=National Institute for Health and Care Excellence, Ph=Philadelphia chromosome, R/R=relapsed/refractory, SCT=stem cell transplant, SACT=systemic anti-cancer therapy, TKI=tyrosine kinase inhibitor.

  1. NICE. Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia. Issued December 2025. Accessed March 2026. https://www.nice.org.uk/guidance/ta1116/resources/obecabtagene-autoleucel-for-treating-relapsed-or-refractory-bcell-precursor-acute-lymphoblastic-leukaemia-pdf-2973530453903557.

  2. AWTTC. Obecabtagene autoleucel (Aucatzyl®). Issued November 2025. Accessed March 2026. https://awttc.nhs.wales/accessing-medicines/medicine-recommendations/obecabtagene-autoleucel-aucatzyl/. 

  3. Summary of Product Characteristics, Aucatzyl 2025.

  4. National Cancer Drugs Fund List. Version 1.385; January 2026. Accessed March 2026. https://www.england.nhs.uk/wp-content/uploads/2017/04/national-cdf-list-ver1.385.pdf.

UK-AUC-0180 | March 2026